Insili Intelligence announced that the company's candidate innovative drug, Rentosertib, is carrying out a phase III clinical trial of Genesis-IPF-3 for idiopathic pulmonary fibrosis. Currently, the first patient enrollment and administration have been completed at Peking Union Medical College Hospital, and the first patient enrollment was completed at Shanghai Pulmonary Hospital on the same day. The trial lasts 52 weeks and is expected to recruit a total of 320 participants from 47 clinical centers in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.